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Abstract
Almost every female classic galactosemia patient develops primary ovarian insufficiency (POI) as a diet-independent
complication of the disease. This is a major concern for patients and their parents, and physicians are often asked
about possible options to preserve fertility. Unfortunately, there are no recommendations on fertility preservation in
this group. The unique pathophysiology of classic galactosemia with a severely reduced follicle pool at an early age
requires an adjusted approach. In this article recommendations for physicians based on current knowledge
concerning galactosemia and fertility preservation are made. Fertility preservation is only likely to be successful in
very young prepubertal patients. In this group, cryopreservation of ovarian tissue is currently the only available
technique. However, this technique is not ready for clinical application, it is considered experimental and reduces
the ovarian reserve. Fertility preservation at an early age also raises ethical questions that should be taken into
account. In addition, spontaneous conception despite POI is well described in classic galactosemia. The uncertainty
surrounding fertility preservation and the significant chance of spontaneous pregnancy warrant counseling towards
conservative application of these techniques. We propose that fertility preservation should only be offered with
appropriate institutional research ethics approval to classic galactosemia girls at a young prepubertal age.
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Introduction
Almost every female patient with classic galactosemia, an
inborn error of galactose metabolism, has primary ovarian
insufficiency (POI) and is confronted with the struggle
that reduced chances of having children presents [1]. Pa-
tients and/or their parents often approach physicians with
questions regarding fertility preservation. Answering these
questions, however, remains difficult, due to the unique
and yet to be determined underlying pathophysiological
mechanisms of POI as well as the lack of experience with
fertility preservation techniques in general and in girls
with classic galactosemia in particular.
Classic galactosemia (ORPHA79239) is caused by defi-
cient activity of galactose-1-phosphate uridyl transferase
(GALT), as a result of mutations in the GALTgene located
on chromosome 9p13. GALT is the second of the three
enzymes in the Leloir pathway, the main pathway of
galactose metabolism. The incidence of classic galactosemia
varies between 1:16.000 [2] and 1:60.000 [3] in Western
countries. Galactose is needed for energy metabolism and
glycosylation of complex molecules. It may be derived from
exogenous (dietary) sources, most importantly lactose from
dairy products, or endogenous production. Deficiency of
the GALT enzyme leads to accumulation of galactose and
its metabolites and results in secondary glycosylation
abnormalities. Patients usually present in the first weeks
of life with signs of liver and renal disease, cataracts and an
Escherichia coli sepsis. Diagnostic tests include elevated
galactose and galactitol in body fluids, elevated Gal-1-P
in erythrocytes, severely diminished enzyme activity
in erythrocytes and mutations in the GALT gene. A
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but cannot prevent the development of later-onset com-
plications, such as cognitive impairment, neurological
sequelae, bone health abnormalities, and, in female patients,
POI with subsequent infertility.
Although POI in classic galactosemia represents a
major concern for these patients and/or their parents
[4], there are no published recommendations concerning
fertility preservation in this group. The current guidelines
in patients with cancer [5-10] may be useful in assessing
the risk-benefit ratio for girls with galactosemia. However,
unlike cancer patients, the mechanisms causing ovarian
dysfunction are unknown and the timing of onset may
begin as early as prenatally [1,11-14]. Therefore, intervening
when the patient reaches adulthood may be too late. As a
consequence, applying fertility preservation options in
very young girls raises medical, legal and ethical questions.
Furthermore, spontaneous pregnancies do occur in this
disease, demonstrating that conception is possible in some
patients.
The aim of this paper is to discuss the different aspects
of fertility loss in female classic galactosemia patients
from a multidisciplinary perspective, and to propose
recommendations for fertility preservation, taking into
account pathophysiology, chances of spontaneous pregnan-
cies and ethical issues. These recommendations are based
on our experiences with classic galactosemia patients and
the currently available literature.
Pathophysiology
Symptoms of POI differ between affected women, vary-
ing from subfertility, to early development of irregular
menstrual cycles and infertility, to primary amenorrhea
and absence of spontaneous puberty [15]. The cause of
POI in classic galactosemia is not yet understood.
Several mechanisms have been postulated, including
direct toxicity of metabolites (i.e. galactose-1-phosphate),
altered gene expression, or aberrant function of hormones
and or receptors due to glycosylation abnormalities
[1,16-18]. It is also possible that not one, but several
mechanisms act in unison to cause POI in classic
galactosemia.
In general, POI can be caused by either the formation
of a smaller primordial follicle pool or more rapid loss
of primordial follicles [15] and there is evidence for both
mechanisms in classic galactosemia. In classic galacto-
semia there is some evidence that the follicle pool at
birth is as large as in girls without this disease. In two
galactosemic neonates, morphologically normal ovaries
with abundant oocytes and normal folliculogenesis
have been reported [19,20]. In another patient, ultra-
sound showed apparently normal ovaries at age 7 [21].
These studies suggest that the primordial follicle
complement is normal initially, but comprehensive
evidence is lacking.
Histological findings show that the ovaries contain a
strongly reduced number of follicles at older, but vari-
able ages. Histological findings in adolescents (aged 16
or 17 years) reveal a strongly reduced number of folli-
cles, varying from far fewer follicles than expected for
age [14] to almost complete absence [22-24]. Data in
younger adolescents or children are lacking. Histological
findings in two adults showed absence of ovarian paren-
chyma [25] and an extremely reduced number of folli-
cles in one subject [26], and a follicle number within the
normal range in the other [26]. Ovarian size and volume
in patients aged 9–21 years assessed with MRI were
comparable to those found in postmenopausal controls
[27]. Ultrasound or laparoscopy/laparotomy in patients
during adolescence or adulthood often shows hypoplas-
tic [24,28,29] or streak ovaries [22,23,25,30], consistent
with the absence of follicles. Of note, streak ovaries were
also found during adolescence in the girl with apparently
normal ovaries at age 7 [21]. Taken together, it is pos-
sible that a normal complement of primordial follicles
forms, but undergoes atresia more rapidly and that the
ovaries can be severely damaged in girls at very young
prepubertal age.
There is also evidence for defective follicle maturation,
which may result from a paucity of follicles able to respond
to stimulation or inability of the follicle to respond to
gonadotropins in galactosemia. The few follicles present
in the ovaries of classic galactosemia patients are mainly
of the primordial type, and maturing follicles are rarely
seen [14,22,23,26,28]. Consistent with the absence of
estrogen production due to absent ovarian activity
[26,27,31], hypoplastic prepubertal uteri were observed
in patients who did not receive estrogen supplementa-
tion [21-23,29,30].
Animal studies suggest that galactose might already
have a direct toxic effect in fetal life. After feeding preg-
nant and lactating Sprague–Dawley rats a high galactose
diet, the offspring had a significant and striking reduc-
tion in the number of small follicles, [11], a reduced
number of primordial germ cells (PGCs) and a conse-
quently smaller gonadal size [32] suggesting impaired
germ cell migration, and a deficient complement of
follicles in some of the exposed animals [33].
An accelerated loss of follicles during life has also been
suggested in several studies. Lai et al. found that the
number of apoptotic granulosa cells of maturing follicles
was higher in Sprague–Dawley rats fed a high galactose
diet than in animals receiving normal chow [34]. The
same has been concluded in a recent study by Banerjee
et al. [35]. Their results in isolated granulosa cells
suggest that galactose exposure leads to an increased
expression of p53, a protein mediating intrinsic death
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atresia. The authors also suggest that attenuated FSH
bioactivity is the underlying cause of the increased p53
expression. The latter is not consistent with failure of
follicle response to exogenous FSH [27,37].
Some animal studies also point to a compromised
maturation. A high galactose diet significantly decreased
the number of healthy growing and antral follicles, whereas
the number of primordial or total atretic follicles was not
affected [38], although other studies suggested that the
primordial follicle count was lower [11]. Similarly, other
studies using the same model demonstrated a decreased
ovulatory response [33,39,40], evidenced by reduced
numbers of corpora lutea.
Both case reports of neonates compared to older girls
and the animal studies suggest that galactosemia results
in increased follicle apoptosis with an accelerated follicle
loss of either primordial follicles or maturing follicles as
the cause of POI [34,35,38]. It might be very difficult to
determine whether the large follicle pool present at birth,
consisting of millions of primordial follicles, is reduced in
classic galactosemia patients unless the decrease is marked.
Animal models indicate a prenatal toxic effect of galacto-
semia but these animal studies, in which animals are fed a
high galactose diet, might not represent human classic
galactosemia completely. Although the histological and
imaging data are very limited and call for a tedious
conclusion, taken together, there seems to be a rapid
decline in the number of primordial follicles either in fetal
life or in early life in this disease, which has to be taken
into account when discussing fertility preservation.
Spontaneous pregnancies in women with classic
galactosemia
Over the past years it has become increasingly clear that
spontaneous pregnancies in classic galactosemia occur,
and occur more frequently than previously thought. In
a cohort of 22 patients with classic galactosemia and
POI, 9 patients tried to conceive, of which 4 succeeded
(44 percent) [41]. Although significant, the small sample
size warrant further studies in a larger cohort. Many
patients were told in the past that they had no chance of
conceiving and therefore may not have tried, which makes
it difficult to determine the exact chance of spontaneous
pregnancy in classic galactosemia. It is important that
patients are aware of the occurrence of spontaneous
pregnancies [2,31,41-43], allowing them both to try to
conceive spontaneously and to avoid unplanned pregnan-
cies. The World Health Organization defines infertility as
a failure to achieve spontaneous pregnancy within twelve
months or more [44]. Therefore we advise physicians to
encourage their patients to try to achieve spontaneous
pregnancy for at least this period of one year. We also
advise physicians to explain that pregnancy should not
be postponed unnecessarily to increase chances of
conception. Importantly, classic galactosemia women
became pregnant despite postmenopausal FSH levels,
extremely low estrogen concentrations, undetectable
Müllerian Inhibitory Substance (MIS) or anti-Müllerian
hormone (AMH) levels [31,45] and the severe Q188R/
Q188R genotype [2,41,43]. Therefore, genotype, enzyme
activity in erythrocytes, and measurement of markers of
ovarian reserve do not appear accurate predictors of
pregnancy chances in this patient population. Besides,
the ovaries of prepubertal girls are very small, even in
healthy girls, limiting the relevance of imaging techniques
in these patients. Of note, most of the women that became
pregnant spontaneously have gone through normal puberty
and reached menarche spontaneously, indicating that
these might be predictive factors for an increased chance
of spontaneous conception [41].
Fertility preservation in classic galactosemia patients
Importantly, fertility preservation data are mainly derived
from cancer patients. The ovaries of a girl affected with
non-ovarian cancer are healthy when there is a need for
fertility preservation. In contrast, the ovaries of classic
galactosemia girls are probably already damaged at an
early age. Therefore, the success rate of the procedures is
probably lower in galactosemic girls. Perhaps the most
important issue to discuss before choosing to apply fertility
preservation techniques is the fact that fertility preserva-
tion does not guarantee future pregnancy. A thorough
evaluation including the abovementioned chance of spon-
taneous pregnancy and the risks and benefits needs to be
taken into account. Three fertility preservation procedures
currently offered to girls and women in need of fertility
preservation are: a. ovarian tissue cryopreservation, b.
mature oocyte cryopreservation and/or c. embryo cryo-
preservation. The latter two techniques require ovarian
stimulation with FSH, whereas cryopreservation of ovarian
tissue does not.
a. Ovarian tissue cryopreservation
In ovarian tissue cryopreservation, one ovary is harvested
through laparoscopy and the cortex tissue is processed
into cortical strips and frozen. When the patient is ready to
conceive, the tissue is transplanted at either an orthotopic
or a heterotopic location in the body. Currently, twenty
healthy infants have been born worldwide as a result of
autotransplantation of the cryopreserved tissue [46]. All
mothers were women with no history of ovarian problems
who were treated with chemotherapy after cancer diagnosis.
However, the method is still experimental and consensus is
lacking on the amount of tissue that needs to be harvested
for cryopreservation [47,48]. The major risk of this tech-
nique is that the graft may not survive due to ischemic
damage, which leads to massive follicular death [49,50].
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[49], the chance of restoring fertility is related to the
number and quality of the primordial follicles in the
transplanted cortical tissue [51]. Therefore, it is possible
that the quantity of ovarian tissue removed should be
influenced by the expected probability of POI [47]. Another
disadvantage of cryopreservation of ovarian tissue is that
this technique might lower the chance of spontaneous
pregnancy, as a result of reduction of the remaining ovar-
ian pool. Moreover, it is also possible that the transplanted
tissue is subject to the same detrimental factors that cause
POI in this patient group.
b. Mature oocyte cryopreservation
In oocyte cryopreservation the patient’s ovaries are stim-
ulated with exogenous FSH, the growing follicles are
punctured transvaginally and the oocytes are extracted
from the follicles. The metaphase II oocytes are frozen
using vitrification, a technique in which high initial
concentrations of cryoprotectant and ultra-rapid cooling
are used to create a glass-like state in a cell without
forming ice crystals. Once the patient desires to conceive,
the oocytes are warmed and consequently fertilized
in a petri dish using a partner’s or donor’s semen
(intracytoplasmatic sperm injection, ICSI). The procedure
of mature oocyte cryopreservation is no longer considered
experimental by multiple international reproduction
societies, including the American Society for Reproductive
Medicine (ASRM) [52]. A recent review of the literature
and meta-analysis suggested that fertilization and preg-
nancy rates were similar with vitrified/warmed oocytes
and fresh oocytes [52]. However, a limitation of this
analysis is that the majority of data is derived from
studies with oocytes obtained from healthy, young donors.
The current recommendations by the ASRM state that
oocyte cryopreservation is recommended for patients
facing infertility due to chemotherapy or other gonadotoxic
therapies, but that more widespread clinic-specific data on
the safety and efficacy of oocyte cryopreservation in donor
populations are needed before universal donor oocyte
banking can be recommended. Therefore, its use in patients
with galactosemia is as yet unclear.
c. Embryo cryopreservation
A third fertility preservation option is embryo cryopreser-
vation, a well-established and successful technique. This
procedure consists of ovarian stimulation, transvaginally
harvesting cumulus oocyte complexes and extraction of
oocytes. The oocytes are fertilized in vitro using a partner’s
or donor’s semen. The fertilized oocytes also develop
in vitro to the embryo stage and are then cryopreserved by
means of vitrification or slow freezing. Once the patient
desires to conceive embryos are warmed and implanted in
t h eu t e r u s .T h ee m b r y os u r v i v a lr a t ei sa p p r o x i m a t e l y9 0 %
when vitrification is used [53]. Pregnancy rates in regular
IVF programs are on average 30% [54].
Since all fertility preservation techniques depend on
the ovarian reserve [55], and considering the apparent
rapid follicle pool decline in classic galactosemia, fertility
preservation in these patients may need to take place
during infancy or early childhood, seriously limiting the
options. Techniques requiring ovarian stimulation are
not suitable for prepubertal girls because of absence of
maturation of the hypothalamic-hypophyseal-ovarian axis
[56], leaving cryopreservation of ovarian tissue the only
available technique for this age group. Fertility preservation
in older, postpubertal classic galactosemia patients is likely
to be unsuccessful as the ovarian reserve may be poor.
Embryo cryopreservation and oocyte cryopreservation are,
in theory, the best options in these patients. However,
both techniques require ovarian stimulation. Ovarian
stimulation in fifteen classic galactosemia patients, aged
15 to 36 years demonstrated poor estradiol production in
all but one [27]. Therefore, the severely reduced follicle
pool limits the use of cryopreservation of embryos and
mature oocytes [1]. It might be an option for those young
classic galactosemic women with a sufficient ovarian
reserve, but these women probably are the women whose
chances of spontaneous conception are highest.
If fertility preservation is not a reasonable option, or if
pregnancy does not occur despite fertility preservation,
another option is adoption or the use of donor oocytes
to achieve pregnancy. The donor can be anonymous or
can be a direct donor, such as a mother or sister. Mothers
of galactosemic girls frequently propose to donate oocytes
for their daughters. It may be necessary to cryopreserve
the mother’s oocytes for the future if the patient is not
ready for children at the time of donation. The ethical
issues resulting from intra familial donation are discussed
below.
In the future, other fertility preservation techniques might
become available. As an alternative for mature oocyte cryo-
preservation, cryopreservation of oocytes extracted from
immature follicles has been evaluated (in vitro maturation,
IVM). Another fertility preservation technique that is
currently being evaluated and might be an option in the
future is freezing and transplantation of the entire ovary
including its vascular system [57,58]. Also the possible
existence of oogonial stem cells [59] and induced pluripo-
tent stem cells [60] might offer therapeutic options for the
future.
Ethical considerations in fertility preservation
Ethical problems arise in all young patients in need of
fertility preservation, regardless of the underlying etiology.
Girls are often too young to decide about fertility preserva-
tion themselves and therefore their parents play a crucial
role in this process. One probably cannot predict with
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daughter will think about a pregnancy in the future. The
parent’s decision may not ultimately reflect the girl’s
wishes when she becomes an adult [8]. In 2005, the
American Society for Reproductive Medicine (ASRM)
stated that fertility preservation can be applied in minors
if this is in the best interest of the child and if the girl gives
her assent [6]. If a girl is too young to give assent, parents
may give consent if the procedure offers a net benefit for
the child. Review of this decision by the ethics committee
of a hospital or another independent body is in our
opinion a must. The same criteria and advice hold true
for fertility preservation techniques that are still considered
experimental, though approved by the institutional ethics
committee. Psychosocial guidance of the girl during the
procedure and further discussion about fertility during
adolescence and adulthood are very important. Moreover,
legislation always plays a role in medical decision-making,
but laws often differ between countries and may not be
specific.
Cryopreservation of ovarian tissue, the most plausible
fertility preservation option for this population, is still
considered experimental and pregnancy rates resulting
from this procedure are uncertain [9]. Recommending
methods that are not yet established may offer false hope
[1]. Therefore, the benefits and harms of every procedure
should be discussed extensively, and chances of spontan-
eous pregnancy in this particular disease despite POI
should be considered.
Intrafamilial oocyte donation might lead to ethical is-
sues including psychosocial pressure on the donor and
recipient, over-attachment of the donor to the offspring,
and role confusion for the persons involved, including
the resulting offspring [61]. The process of intrafamilial
donation requires the help of multiple professionals, a
thorough screening of the donor, psychological counseling
of both the donor and the recipient and extensive
informing about legal parenting relations [61,62].
Discussion
As a consequence of the severe depletion of the follicle
pool that probably occurs prenatally or early in childhood
in classic galactosemia patients, fertility preservation in
this group is only likely to be successful in very young
patients. Oocyte cryopreservation after ovarian stimulation
will likely not be successful in most women with classic
galactosemia. It might be useful in women with a sufficient
ovarian reserve who wish to postpone pregnancy. Ovarian
tissue cryopreservation, the only available technique at a
young age, has several important disadvantages, including
the experimental character of the procedure and the
reduced chances of spontaneous pregnancy. Therefore, the
technique should probably not yet be offered in a clinical
setting, but could be considered on research basis.
In general, classic galactosemia patients may have below-
average cognitive functioning [2,63-65] and social-emotional
problems [66,67], which might affect the ability to raise
children. However, the severity of these impairments will
not be clear at the time of fertility preservation, since
this can change over time [68]. At the time of fertility
preservation, physicians should explain to the patient’s
parents that some patients might not develop enough
parental competency and that this might prevent the use
of cryopreserved tissue. In adulthood, when the cognitive
and ovarian phenotype of the patient is clear and when
psychological tests have been performed, the adult patient
can decide if she wishes to have children and if she wants
to use the cryopreserved tissue in order to achieve this.
At that time, physicians and the ethics committee of the
hospital or another independent body should evaluate
whether the patient has adequate parental competency,
in case this is doubtful. This is consistent with other
fertility preservation procedures, for instance in pediatric
cancer patients [10].
Physicians confronted with questions regarding POI
and fertility preservation in classic galactosemia, should
emphasize that pregnancy has been repeatedly reported
despite POI and they should not discourage patients to
try to conceive spontaneously. Noteworthy, girls with a
spontaneous puberty are likely to have higher chances of
spontaneous pregnancy. Furthermore the risk of post-
poning pregnancy needs to be discussed as well, since in
galactosemic women, as in any woman, fertility declines
with age, lowering the risk of spontaneous conception.
However, due to the unknown course of ovarian function
and the unknown pathophysiological mechanism of
POI in classic galactosemia, decisions about fertility
and fertility preservation remain difficult for patients,
parents and physicians.
Conclusions and recommendations
Based on the current knowledge about classic galactosemia
and its pathophysiology, we recommend that fertility
preservation should not be offered to these patients as
common practice (see the ‘Our recommendations regarding
fertility preservation in female classic galactosemia patients’
subsection). If it is part of institutional research ethics
approved research it might be taken into careful consid-
eration. Cryopreservation of ovarian tissue in young
prepubertal girls is at this moment the procedure of
choice. At a later age, estimated success rates are too
low since the ovarian damage is probably already too
prominent. Trying to achieve spontaneous pregnancy
seems to be the best option for older girls and women.
Another option for classic galactosemic girls and women
might be oocyte donation, both anonymous donation and
intrafamilial donation. We currently do not recommend
intrafamilial donation by the mother, as mentioned above.
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mother is considered, psychological screening and ex-
tensive counseling are required, according to previously
mentioned guidelines [61].
Finally, we recommend engagement of an independent
review board in the process of fertility preservation at
minimum two points in the process: when the parental
decision to preserve their daughter’s ovarian tissue is
considered, but also when the patient wishes to use the
preserved tissue, as the parental capacity of the patient
should be reviewed.
Our recommendations regarding fertility preservation in
female classic galactosemia patients
 Physicians should emphasize that spontaneous
pregnancies occur in women with classic
galactosemia, even after POI diagnosis.
 If fertility preservation is desired, cryopreservation
at an early prepubertal age as a part of approved
research currently seems to be the best option.
 The ethics committee of the hospital or another
independent body should review the parent’s
decision before the fertility preservation procedure.
 The ethics committee of the hospital or another
independent body should be involved in the decision
making surrounding the use of the cryopreserved
material.
 If a patient desires pregnancy, a one-year window
for attempting spontaneous pregnancy is advised to
avoid unnecessary use of assisted reproductive
techniques.
 Anonymous or intrafamilial oocyte donation might
be another option for classic galactosemia patients if
pregnancy does not occur.
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